Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of pyrazolopyrimidine derivative, its preparation method and its application in medicine preparation

A technology of azolopyrimidine and derivatives, which is applied in the field of pyrazolopyrimidine derivatives and their preparation, to achieve the effects of inhibiting proliferation and significant targeted therapy

Active Publication Date: 2021-09-03
GUANGXI WUZHOU PHARMA GRP
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There is currently a lack of new generation FLT3-targeted drugs developed for quizartinib resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pyrazolopyrimidine derivative, its preparation method and its application in medicine preparation
  • A kind of pyrazolopyrimidine derivative, its preparation method and its application in medicine preparation
  • A kind of pyrazolopyrimidine derivative, its preparation method and its application in medicine preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] (1) Add 4-amino-2-fluorophenol (6.4g, 50mmol) and sodium hydroxide (0.80g, 50mmol) to 100mL of water, stir at room temperature for 30 minutes, then add potassium carbonate (7.2g, 52mmol), and The temperature was raised to 60°C, and the tetrahydrofuran solution of 4-chloro-6,7-dimethoxyquinazoline (13.5g, 60mmol) was slowly added to the above reaction solution, and the reaction was stopped after 2 hours, and the tetrahydrofuran solution of the reaction system was After evaporating to dryness, the remaining system was extracted twice with ethyl acetate and water, and the ethyl acetate layer was dried with anhydrous magnesium sulfate and then spin-dried to obtain 4-(6,7-dimethoxyquinazolin-4-oxyl) -3-fluoroaniline (8.9g, 28mmol);

[0025] (2) Dissolve 3-amino-5-tert-butylisoxazole (4.2g, 30mmol) in 150mL of tetrahydrofuran, slowly drop into the solution of triphosgene (9g, 30mmol) in tetrahydrofuran, and continue stirring for 2h after the drop is complete. Add 25g of pota...

Embodiment 2

[0028] (1) Add 4-amino-2-fluorophenol (6.5g, 51mmol) to 120mL of acetonitrile, stir and dissolve at room temperature, then add triethylamine (15.2g, 150mmol), while raising the temperature to 60°C, and 4- The acetonitrile solution of chloro-6,7-dimethoxyquinazoline (13.5g, 60mmol) was slowly added to the above reaction solution, and the reaction was stopped after 3 hours. After the acetonitrile in the reaction system was evaporated to dryness, the remaining system was washed with ethyl acetate Esters and water were extracted twice, and the ethyl acetate layer was dried with anhydrous magnesium sulfate and then spin-dried to give 4-(6,7-dimethoxyquinazolin-4-oxyl)-3-fluoroaniline (7.9g, 25mmol);

[0029] (2) Dissolve 3-amino-5-tert-butylisoxazole (4.2g, 30mmol) in 150mL of acetonitrile, slowly drop it into triphosgene (9g, 30mmol) in acetonitrile, and continue stirring for 2h after dropping. Add 19g of triethylamine to the reaction solution, then add 4-(6,7-dimethoxyquinazolin...

Embodiment 3

[0032] (1) Add 4-amino-2-fluorophenol (6.5g, 51mmol) into 100mL of ethyl acetate, stir and dissolve at room temperature, add diisopropylethylamine (19.4g, 150mmol), and raise the temperature to 60°C , and the ethyl acetate solution of 4-chloro-6,7-dimethoxyquinazoline (13.5g, 60mmol) was slowly added to the above reaction solution, the reaction was stopped after 2 hours, extracted twice with water, ethyl acetate The ester layer was dried with anhydrous magnesium sulfate and then spin-dried to give 4-(6,7-dimethoxyquinazolin-4-oxyl)-3-fluoroaniline (9.1g, 29mmol);

[0033](2) Dissolve 3-amino-5-tert-butylisoxazole (4.2g, 30mmol) in 150mL of dichloroethane, and slowly drop it into the dichloroethane of triphosgene (9g, 30mmol). Stirring was continued for 2h. Add 24g of diisopropylethylamine in the reaction solution, then add 4-(6,7-dimethoxyquinazoline-4-oxyl group)-3-fluoroaniline (9.1g, 29mmol), at 80 The reaction was stopped after 8 hours at reflux at °C. Spin-dry dichloro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to a pyrazolopyrimidine derivative, a preparation method thereof and an application in medicine preparation. The pyrazolopyrimidine derivative is shown in formula I: the pyrazolopyrimidine derivative provided by the present invention has a targeting effect on FLT3 kinase, and can effectively treat diseases with FLT3 mutation and leukemia.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a pyrazolopyrimidine derivative, a preparation method thereof and an application in medicine preparation. Background technique [0002] Quizartinib (AC220), developed by Ambit Corporation of the United States, is a second-generation FLT3 inhibitor. Compared with the first-generation FLT3 inhibitor, it is highly selective for FLT3. Among them, the compound achieved a complete remission rate of 44% to 54%. Molecular mechanism studies have shown that after continuous treatment with quizartinib, the FLT3 kinase has a secondary mutation on the basis of the original mutation, resulting in difficulty in drug combination and drug resistance. The main mutation sites were concentrated in the 835th aspartic acid (D835) in the "activation loop" and the 691st phenylalanine (F691) in the "gatekeeper". [0003] Literature 1 (Activity of ponatinib against clinically-relevant AC220-resistant ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D413/12A61K31/517A61P35/02
CPCC07D413/12
Inventor 李柏霖聂雪玫韦杰欧阳静波陈焕展黄宇声刘冠萍
Owner GUANGXI WUZHOU PHARMA GRP